NO20014508L - Fremgangsmåte for acylering av peptider, og nye acyleringsmidler - Google Patents

Fremgangsmåte for acylering av peptider, og nye acyleringsmidler

Info

Publication number
NO20014508L
NO20014508L NO20014508A NO20014508A NO20014508L NO 20014508 L NO20014508 L NO 20014508L NO 20014508 A NO20014508 A NO 20014508A NO 20014508 A NO20014508 A NO 20014508A NO 20014508 L NO20014508 L NO 20014508L
Authority
NO
Norway
Prior art keywords
acylating
new
peptides
agents
acylating agents
Prior art date
Application number
NO20014508A
Other languages
English (en)
Other versions
NO20014508D0 (no
Inventor
Louis Brammer Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20014508D0 publication Critical patent/NO20014508D0/no
Publication of NO20014508L publication Critical patent/NO20014508L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
NO20014508A 1999-03-17 2001-09-17 Fremgangsmåte for acylering av peptider, og nye acyleringsmidler NO20014508L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99610019 1999-03-17
EP00910573A EP1163211B1 (en) 1999-03-17 2000-03-16 Method for acylating peptides and proteins
PCT/DK2000/000117 WO2000055119A1 (en) 1999-03-17 2000-03-16 Method for acylating peptides and novel acylating agents

Publications (2)

Publication Number Publication Date
NO20014508D0 NO20014508D0 (no) 2001-09-17
NO20014508L true NO20014508L (no) 2001-09-17

Family

ID=26074622

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014508A NO20014508L (no) 1999-03-17 2001-09-17 Fremgangsmåte for acylering av peptider, og nye acyleringsmidler

Country Status (16)

Country Link
EP (2) EP1163211B1 (no)
CN (1) CN1344248A (no)
AT (1) ATE409193T1 (no)
AU (1) AU3273500A (no)
BR (1) BR0009040A (no)
CA (1) CA2361830A1 (no)
CZ (1) CZ20013018A3 (no)
DE (1) DE60040333D1 (no)
ES (1) ES2315226T3 (no)
HU (1) HUP0200297A3 (no)
IL (1) IL144989A0 (no)
NO (1) NO20014508L (no)
PL (1) PL351326A1 (no)
RU (1) RU2001128068A (no)
WO (1) WO2000055119A1 (no)
ZA (1) ZA200106884B (no)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
ATE411337T1 (de) * 2001-07-24 2008-10-15 Novo Nordisk As Verfahren zur herstellung acylierter polypeptide
AU2002355160A1 (en) * 2001-07-24 2003-02-17 Novo Nordisk A/S Method for making acylated polypeptides
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
IL160493A0 (en) 2001-08-23 2004-07-25 Lilly Co Eli Glucagon-like peptide-1 analogs
US7273921B2 (en) * 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
PL210455B1 (pl) * 2002-09-25 2012-01-31 Novo Nordisk As Sposób otrzymywania acylowanych peptydów
EP1543030A2 (en) 2002-09-25 2005-06-22 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
CN102940879B (zh) 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
ATE529126T1 (de) 2003-06-03 2011-11-15 Novo Nordisk As Stabilisierte pharmazeutische peptid zusammensetzungen
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
ES2442223T3 (es) 2004-08-31 2014-02-10 Novo Nordisk A/S Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
CN102027005A (zh) 2008-05-15 2011-04-20 诺沃-诺迪斯克有限公司 通过固相合成制备的肽的纯化
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
EA020520B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
EP2370459A1 (en) 2008-12-15 2011-10-05 Zealand Pharma A/S Glucagon analogues
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
MX343360B (es) 2010-04-27 2016-11-03 Zealand Pharma As Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CA2802510A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
MX2012014961A (es) 2010-06-24 2013-02-26 Zealand Pharma As Analogos de glucagon.
UY33872A (es) 2011-01-20 2012-08-31 Zealand Pharma As Uso de análogos de glucagón acilados
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN104144704B (zh) 2011-11-03 2018-03-23 西兰制药公司 Glp‑1受体激动剂肽胃泌素缀合物
IN2014MN02304A (no) 2012-05-03 2015-08-07 Zealand Pharma As
EP2844670B1 (en) 2012-05-03 2017-12-06 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
AR091866A1 (es) 2012-07-23 2015-03-04 Zealand Pharma As Analogos del glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
ES2688367T3 (es) 2012-12-21 2018-11-02 Sanofi Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
EP2968443B1 (en) 2013-03-15 2021-09-29 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
BR112015030948A2 (pt) 2013-06-20 2017-09-19 Novo Nordisk As Derivados de glp-1 e usos dos mesmos
JP6139712B2 (ja) 2013-07-04 2017-05-31 ノヴォ ノルディスク アー／エス Ｇｌｐ−１様ペプチドの誘導体及びその使用
UA122767C2 (uk) 2013-10-17 2021-01-06 Зіленд Фарма А/С Ацильований аналог глюкагону
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
NZ726337A (en) 2014-05-16 2023-10-27 Protagonist Therapeutics Inc Α4β7 integrin thioether peptide antagonists
CN104558097A (zh) * 2014-05-20 2015-04-29 广东东阳光药业有限公司 肽的酰化方法
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CA2955460A1 (en) 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
ES2739289T3 (es) 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
AU2016232218B2 (en) 2015-03-18 2020-09-10 Boehringer Ingelheim International Gmbh Amylin analogues
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017127007A1 (en) 2016-01-20 2017-07-27 Poypeptide Laboratories Holding (Ppl) Ab METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
EP3196206A1 (en) 2016-01-20 2017-07-26 Lonza Ltd Method for preparation of liraglutide
EP3205660A1 (en) 2016-02-10 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of peptides with pswang linker
EP3205664A1 (en) 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of liraglutide using bal linker
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
WO2018104346A1 (en) 2016-12-05 2018-06-14 Nuritas Limited Compositions comprising peptide wkdeagkplvk
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR20200135797A (ko) 2018-02-27 2020-12-03 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이들의 의학적 용도
WO2020127476A1 (en) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CN111909073A (zh) * 2019-05-10 2020-11-10 江苏万邦医药科技有限公司 一种制备高纯度脂肪酸衍生物的方法
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
KR20220066287A (ko) 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations
WO2021198196A1 (en) 2020-03-30 2021-10-07 Zealand Pharma A/S Glp-1/glp-2 dual agonists
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
PE20240631A1 (es) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23
EP4281039A2 (en) 2021-01-25 2023-11-29 Mylan Ireland Limited Pharmaceutical glp peptide compositions and methods of preparation thereof
WO2023031380A1 (en) 2021-09-03 2023-03-09 Zealand Pharma A/S Dosage regime
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
EP0938502B1 (en) 1996-07-11 2004-10-06 Novo Nordisk A/S Selective acylation method
BRPI9711437B8 (pt) * 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action

Also Published As

Publication number Publication date
NO20014508D0 (no) 2001-09-17
ZA200106884B (en) 2002-03-01
PL351326A1 (en) 2003-04-07
WO2000055119A1 (en) 2000-09-21
ES2315226T3 (es) 2009-04-01
DE60040333D1 (de) 2008-11-06
EP1163211A1 (en) 2001-12-19
EP1956000A1 (en) 2008-08-13
ATE409193T1 (de) 2008-10-15
EP1956000B1 (en) 2016-10-05
IL144989A0 (en) 2002-06-30
HUP0200297A2 (en) 2002-06-29
CA2361830A1 (en) 2000-09-21
CN1344248A (zh) 2002-04-10
BR0009040A (pt) 2001-12-18
EP1163211B1 (en) 2008-09-24
HUP0200297A3 (en) 2002-09-30
RU2001128068A (ru) 2004-02-20
CZ20013018A3 (cs) 2002-02-13
AU3273500A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
NO20014508D0 (no) Fremgangsmåte for acylering av peptider, og nye acyleringsmidler
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
DE69739035D1 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
ATE254138T1 (de) An den erythropoietin-rezeptor bindende zusammensetzungen und peptide
HU9200548D0 (en) Improved activity process of recombined proteins
ATE321774T1 (de) An aminosaeure angereicherte speicherproteine, insbesondere an lysin angereicherte mais-gamma- zeine, und diese exprimierende pflanzen
BR0010720A (pt) Peptìdeos de neisseria antigênicos
DE69129865D1 (de) Osteogene peptide
FI880017A (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
SE8801701D0 (sv) Production technology based on enzymic method
ITMI951764A0 (it) Peptide sintetasi ingegnerizzate e loro impiego per la produzione via non-ribosomale di peptidi
PT896615E (pt) Peptido proveniente de uma forma soluvel de acetilcolinesterase activo como modulador dos canais de calcio
EP0716591A4 (en) METHODS AND COMPOSITIONS FOR FIXING TAU AND MAP2c PROTEINS
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
EP1132402A4 (en) PEPTIDE FRAGMENTS WITH CELL DEATH PREVENTIVE ACTIVITY
WO2003002730A3 (fr) Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode
DE3852105T2 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
DE60236330D1 (de) Biologisch aktive Peptide
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
DK0975742T3 (da) Aminopeptidase, der stammer fra Bacillus licheniformis og fremgangsmåde til fremstilling af et natur-type proteiner
DE60120357D1 (de) Haemophilus influenza äusseres membranprotein und verwendung davon als impstoff
TH17162A (th) สารผสมฟอกจากที่ประกอบด้วยเอนไซม์โพรทีเอส

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application